Search:

Home Index Back issues Contact

This item requires a subscription.

Erythropoietin management
BJCM, Volume 1, Number 3.

The burden of fatigue has now overtaken nausea and pain as the most distressing symptom during chemotherapy.1 Clinician awareness of fatigue has also been increased by the steady stream of randomised trials in literature, improvements in patient information materials,2 and campaigns from advocacy groups. However, not so long ago studies showed that clinicians underestimated the importance of fatigue in their patients.

To view this item, select one of the options below:

Purchase access

In order to view articles you will need to pay a subscription for 24-hour access. You can view all articles on this site during the subscription period.
Please click here to subscribe.
 

Sign in

If you are already have a subscription, please sign in here.

email address

Password

Forgotten your password?

Important

All the articles are in PDF format.

To view the articles you will need Adobe Acrobat Reader.

To download a copy, free of charge,
please click here.

 
Help
  If you need help accessing this site, please click here.

 


The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title British Journal of Cancer Management is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk